Paclitaxel Fresenius 30mg / 5ml. 100mg / 5ml. 300mg / 50ml Infusion
PDF Leaflet Revision Date: 3 May 2018
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced ovarian, breast, and non-small cell lung cancer.
Dosage (summary)
135-175 mg/mu00b2 IV over 3-24 hours every 3 weeks, pre-medicate before administration.
Special Populations
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- Caution with ketoconazole
- Increased doxorubicin levels when combined
Contraindications
- Severe hypersensitivity to paclitaxel
- Baseline neutrophils <1500/mmu00b3
- Pregnancy and lactation
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
- Nausea
- Vomiting
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Do not drive if experiencing dizziness
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiovascular events
Important Disclaimer
The Paclitaxel Fresenius 30mg / 5ml. 100mg / 5ml. 300mg / 50ml Infusion professional information leaflet below is the property of Fresenius Kabi and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
